P/E ratio for Ultragenyx (RARE)
P/E ratio as of April 2024 (TTM): -4.32
According to Ultragenyx's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.31934. At the end of 2022 the company had a P/E ratio of -4.58.
P/E ratio history for Ultragenyx from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.58 | -63.43% |
| 2021 | -12.5 | -71.57% |
| 2020 | -44.1 | 634.94% |
| 2019 | -6.00 | -46.19% |
| 2018 | -11.1 | 70.91% |
| 2017 | -6.52 | -42.48% |
| 2016 | -11.3 | -60.17% |
| 2015 | -28.5 | 50.54% |
| 2014 | -18.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Lexicon Pharmaceuticals
LXRX | -2.32 | -46.21% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -0.6738 | -84.40% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | -16.1 | 272.05% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 104 | -2,509.09% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.